Presentation is loading. Please wait.

Presentation is loading. Please wait.

Commercialization of Ossabaw Swine for Biomedical Research Yingkai Cheng Jessie Lu Jeff Fill Robbie Singh Ziqing Liu Tom West February 23, 2011.

Similar presentations


Presentation on theme: "Commercialization of Ossabaw Swine for Biomedical Research Yingkai Cheng Jessie Lu Jeff Fill Robbie Singh Ziqing Liu Tom West February 23, 2011."— Presentation transcript:

1 Commercialization of Ossabaw Swine for Biomedical Research Yingkai Cheng Jessie Lu Jeff Fill Robbie Singh Ziqing Liu Tom West February 23, 2011

2 Objective & Short-term Goal Project Objective: Demonstrate that Ossabaw Swine research is a viable model being based in the University and as a commercialized venture Short-term Goal: Demonstrate viability of the Ossabaw Swine Resource Center by: Demonstrating the advantage of using Ossabaws in research Proposing implementation of a Tiered Fee Schedule

3 Improving Revenues in Short-term Currently Revenues< Costs Price increases on contract studies & swine sales Internal Studies (Indiana’s universities): 11% price increase External Studies (all others): 17.5% price increase Additional Services * Imaging Studies (CT, MRI) * Organ/ Tissue/ Other Parts $75.00 + Service Fees

4 Long-term Goals Long-term Goal: Prepare a value proposition to commercialize / license sale of Ossabaw swines to a prospective vendor The path to commercialization will: Maintain solvency of the Ossabaw Swine Resource Optimize available funding options Respect required University procedures Suggest marketing & promotional avenues Establish milestones for funding and strategic initiatives

5 Market Segmentation 50% 39% 9% 2% Source: PubMed keyword search: breed + miniature swine

6 Why use Ossabaw Swines? CharacteristicYucatan (Yuc)Ossabaw (Oss) ObesityNoOss > Yuc Insulin resistanceNoYes Glucose intolerance (IGT)NoYes Dyslipidemia ( ↑ LDL/HDL)Yes Dyslipidemia ( ↑ triglycerides)NoYes HypertensionNoYes * Metabolic syndrome model * Exercise physiology * Percutanous catheterization, stents * Xenotransplantation * Cutaneous wound healing * Polycystic ovary syndrome * Neonatology *Lithotripsy treatment of kidney stones * Endothelial progenitor cell biology * Alzheimer’s disease * Cardiovascular disease model * Kidney function and disease * Dietary probiotics * Electrical stimulation of gastrointestinal tract * Bladder function and disease * Pancreatic beta cell function and isolation * Non-alcoholic steatohepatitis * Adrenal hormone regulation * Diffuse idiopathic skeletal hyperostosis * Vocal cord physiology Uses of Ossabaw Swine for Translational Research

7 Path to Commercialization Negotiation with Exemplar Revenues 2011-1420152016-17 Phase 1Phase 2Phase 3Phase 4 Address CTSI Member Concerns IU / Purdue IRBs Implementation 2014 Joint Operations Ossabaw Swine Resource

8 Commercialization Plan Inflection Points R&D Partnership with Exemplar Genetics Royalties and milestone payments Transgenic & gene knock-out capabilities Continued research at Ossabaw Resource Upfront licensing fee Milestone payments 1% royalty on sales Profits split: 55%: Ossabaw Resource 45%: Exemplar Genetics Commercialization Plan

9 Costs & Considerations Ossabaw Swine Resource: Pays 50% to Purdue Milestones: $2.25 M Royalties: $8.1 M 55% Revenue: $23.3M Total cost: $2.3 M NPV: $1.3 M (best) NPV: $0.385 M (worst) ROI: 28.7% Ossabaw Swine Resource: Revenue Growth Increase Market Visibility Conferences Clients’ publications Ossabaw website LARC at IUSM Exemplar Genetics Costs Milestone payments Signing: $1 million (M) Year 6: $0.5 M Year 12:$0.75 M Royalties Paid: 1% Total cost: $1.94 M NPV: $655,933 (best) NPV: $55,000 (worst) ROI: 21.2% 2011-142015-30 Phase 1-2 Phase 3-4

10 NPV Summary for Exemplar Assumptions: Price growth rate is in accordance with hypothetical US inflation rate, plus annual price growth rate Between current & new clients, achieve 10% market share Annual price growth keeps pace with inflation plus price growth rate (7%); in 2020 when transgenics / knockout models developed, mark-up is 25% Discount rate= 30%

11 NPV Summary for Ossabaw Swine Resource

12 Recommendations 2011-14: Increase Revenues by expanding client base Market Ossabaws to Universities & Life Science companies in Indiana Increase National visibility through conferences, journals, Website: http://physiology.medicine.iu.edu/people-in-physiology/michael- sturek-ph-d/#ossabaw-miniature-swine http://physiology.medicine.iu.edu/people-in-physiology/michael- sturek-ph-d/#ossabaw-miniature-swine Adopt the proposed tiered pricing system for internal & external clients

13 Recommendations cont’d. 2015: Form R&D Partnership with Exemplar Genetics (Iowa) Exemplar Genetics provides desired expertise in transgenic & knock-out models An R&D partnership allows Ossabaw Swine Resource to continue their research work

14 Thank You! Questions?


Download ppt "Commercialization of Ossabaw Swine for Biomedical Research Yingkai Cheng Jessie Lu Jeff Fill Robbie Singh Ziqing Liu Tom West February 23, 2011."

Similar presentations


Ads by Google